Cargando…
Biologic Therapies in Polyarticular Juvenile Idiopathic Arthritis. Comparison of Long‐Term Safety Data from the German BIKER Registry
OBJECTIVE: Biologics have an important role in the treatment of juvenile idiopathic arthritis (JIA). Long‐term safety data are limited. Direct comparison of different agents regarding occurrence of adverse events (AEs), especially of rare events, requires large quantities of patient years. In this a...
Autores principales: | Klein, Ariane, Becker, Ingrid, Minden, Kirsten, Hospach, Anton, Schwarz, Tobias, Foeldvari, Ivan, Huegle, Boris, Borte, Michael, Weller‐Heinemann, Frank, Dressler, Frank, Kuemmerle‐Deschner, Jasmin, Oommen, Prasad Thomas, Foell, Dirk, Trauzeddel, Ralf, Rietschel, Christoph, Horneff, Gerd |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6957918/ https://www.ncbi.nlm.nih.gov/pubmed/31943968 http://dx.doi.org/10.1002/acr2.11091 |
Ejemplares similares
-
Long-term safety and effectiveness of etanercept in JIA: an 18-year experience from the BiKeR registry
por: Armaroli, Giulia, et al.
Publicado: (2020) -
Comparative risk of infections among real-world users of biologics for juvenile idiopathic arthritis: data from the German BIKER registry
por: Thiele, Franz, et al.
Publicado: (2021) -
Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry
por: Horneff, Gerd, et al.
Publicado: (2017) -
Outcome of children with oligoarticular juvenile idiopathic arthritis compared to polyarthritis on methotrexate- data of the German BIKER registry
por: Raab, A., et al.
Publicado: (2021) -
Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab
por: Horneff, Gerd, et al.
Publicado: (2016)